Netramark Holdings Inc.

NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting

NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum

NETRAMARK POSITIONED TO ADVANCE PSYCHEDELIC CLINICAL TRIALS FOLLOWING U.S. EXECUTIVE ORDER, SUPPORTED BY PEER-REVIEWED RESEARCH AND ACTIVE PROGRAMS

NETRAMARK COMMENTS ON U.S. EXECUTIVE ORDER TO ACCELERATE TREATMENTS FOR SERIOUS MENTAL ILLNESS AND HIGHLIGHTS THE NEED FOR REGULATORY-GRADE TRIAL DESIGN IN PSYCHEDELIC DEVELOPMENT

NETRAMARK-AUTHORED, PEER-REVIEWED ARTICLE SUGGESTS PSYCHEDELICS MIGHT NOT ONLY AFFECT BRAIN CHEMISTRY, THEY MAY ALSO INVOLVE QUANTUM-LEVEL PROCESSES INSIDE THE BRAIN

NETRAMARK ANNOUNCES STRATEGIC ONCOLOGY RESEARCH COLLABORATION WITH FONDAZIONE PER LA MEDICINA PERSONALIZZATA TO ANALYZE LANDMARK ROME TRIAL DATASET

NETRAMARK UNVEILS AI-DISCOVERED TREATMENT-RESPONSIVE SUBGROUPS IN A4 ALZHEIMER'S TRIAL AT AD/PD CONFERENCE

Report of exempt distribution (45-106F1).pdf

Notice.pdf

Report of exempt distribution (45-106F1).pdf

NETRAMARK AND CAMH ANNOUNCE RESEARCH AWARD TO ADVANCE AI-DRIVEN DISCOVERY IN SCHIZOPHRENIA AND DEPRESSION

NETRAMARK ACHIEVES MAJOR FDA MILESTONE

NETRAMARK CONTINUES EXPANSION INTO PHASE 3 PROGRAMS WITH CONTRACT FROM GLOBAL BIOPHARMACEUTICAL COMPANY

NetraAI Study Accepted for Publication in npj Digital Medicine, Part of the Nature Portfolio

NETRAMARK SIGNS FOUR NEW CONTRACTS WITH A LEADING GLOBAL PHARMACEUTICAL COMPANY TO ENHANCE CLINICAL TRIAL INSIGHTS

News release - English.pdf

Material change report - English.pdf

Notice.pdf

Letter from former auditor.pdf

Letter from successor auditor.pdf

News release - English.pdf

News release - English.pdf

News release - English.pdf

News release - English.pdf

News release - English.pdf